C9 and amyotrophic lateral sclerosis: This innovation enables rapid and sensitive detection of toxic polyglycine-proline biomarkers in cerebrospinal fluid (CSF), achieving effective differentiation between C9orf72-positive (C9+) and negative (C9-) ALS subtypes through quantitative and qualitative pathological biomarker recognition [111,112].